NEU 0.45% $20.00 neuren pharmaceuticals limited

Do the results of your analysis make the case for existing...

  1. 43 Posts.
    lightbulb Created with Sketch. 35
    Do the results of your analysis make the case for existing Neuren shareholders to consider also taking a position in Acadia now, because (subject to the risks of the acquiror being a different entity), Acadia is the likely suitor, and NNZ-2591 would not be subject to anyone’s consent rights post acquisition, which would increase the value of NNZ-2591?
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$20.00
Change
0.090(0.45%)
Mkt cap ! $2.556B
Open High Low Value Volume
$19.88 $20.07 $19.73 $11.80M 591.1K

Buyers (Bids)

No. Vol. Price($)
2 5901 $19.97
 

Sellers (Offers)

Price($) Vol. No.
$20.00 3262 5
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.